How and why should adherence to antiretroviral therapy be monitored today?;Cómo y por qué debe monitorizarse la adherencia al tratamiento antirretroviral en la actualidad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue 10, 2002, Pages 481-483

  Knobel, Hernando ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL ACTIVITY; DRUG MONITORING; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; TREATMENT PLANNING;

EID: 0036904044     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0213-005x(02)72849-8     Document Type: Editorial

References (22)

1. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998;129:503-5.
2. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.
3. Nieuwkerk P, Gisolf E, Sprangers M, Danner S. Adherence over 48 weeks in an antiretroviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antivir Ther 2001;6: 97-103.
4. Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, Lopez-Colomes JL, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001;15:193-9.
5. Le MV, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21-9.
6. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000;1:36-46.
7. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:435-42.
8. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000;24:123-8.
9. Duran S, Solas C, Spire B, Carrieri MP, Fuzibet JG, Costagliola D, et al. "Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?". A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001;15:1075-7.
10. Steiner JF, Prochaska AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997;50: 105-16.
11. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-8.
12. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to Protease Inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
13. Deeks SG. Determinants of virologic response to antiretroviral therapy: Implications for long-term strategies. Clin Infect Dis 2000;30(Suppl 2):S177-84.
14. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparision of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-23.
15. Martin J, Escobar I, Rubio R, Sabugal G, Gascon J, Pulido F, et al. Study of the validity of a Questionnaire to asses the adherence to therapy in patients infected by HIV. HIV Clinical Trials 2001;2:31-7.
16. Gao X, Nau DP. Congruence of three self-report measures of medication adherence among HIV patients. Ann Pharmacother 2000;34:1117-22.
17. Knobel H, Alonso J, Casado J, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 2002;16:605-13.
18. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl 2):S143-51.
19. Knobel H, Codina C, Miró JM, Carmona A, García B, Antela A, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia del tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2000;18:27-39.
20. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-77.
21. Codina C, Martinez M, Tuset M, Del Cacho E, Martín MT, Miró JM, et al. Comparación de tres métodos de cálculo de adherencia en pacientes con tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2002;20:484-90.
22. Martín-Sánchez V, Ortega-Valín L, Pérez-Simón M, Mostaza-Fernández JL, Ortiz de Urbina J, Rodríguez-María M, et al. Factores predictivos de no adhesión al tratamiento antirretroviral de gran actividad. Enferm Infecc Microbiol Clin 2002;20:491-7.